|
| |
CRORCT Global is a Regional CRO located in Saint-Petersburg Russia, performing clinical research services across the breadth of the Russian Federation, former Soviet Republics and Eastern Europe.
Since 2001 RCT Global has expanded it’s experience across numerous therapeutic areas working with international clients from across the globe. Whether you are looking for full clinical support to include site selection, monitoring, project management, regulatory, import/export, drug storage, and medical writing; or only interested in an individual service to address an urgent need, you can count on us to handle your requirements professionally and completely.
The Company was established by a group of research professionals focused on introducing Russian patients to Western medicines that previously were out of reach for the majority of the Russian population. RCT Global understands the synergistic benefits of providing Russian patients access to both current and experimental medicines while at the same time providing Western Pharmaceutical and Biotech Companies access to a large and compliant patient population.
| Contact Details: |
| 256 Bunn Drive Suite 6 |
| Princeton |
| New Jersey |
| 08540 |
| United States of America |
| Tel: | 1 609 731 2225 |
| Fax: | |
| Email: | info@cro-rct.ru |
| WWW: | www.cro-rct.ru/
|
|
Loading...
|
Recent Publications by CRO: |  |
Institutional shared resources and translational cancer research.
The development and maintenance of adequate shared infrastructures is... | 5th November, 2009
| Centro di Riferimento Oncologico, IRCCS, I-33081 Aviano PN Aviano, Italy.
| J Transl Med. 2009 Jun 29;7:54.
DOI Direct Link |
Galectin-10, eosinophils, and celiac disease.
Celiac disease (CD) is a chronic intestinal disease caused by intolerance... | 30th October, 2009
| Experimental and Clinical Pharmacology Unit, Istituto Di Ricovero e Cura a
| Ann N Y Acad Sci. 2009 Sep;1173:357-64.
DOI Direct Link |
Clonal CD27+ CD19+ B cell expansion through inhibition of FC gammaIIR in HCV(+) cryoglobulinemic patients.
Persistent HCV infection may be associated with extrahepatic... | 30th October, 2009
| Experimental and Clinical Pharmacology Unit, DOMERT, Molecular Oncology
| Ann N Y Acad Sci. 2009 Sep;1173:326-33.
DOI Direct Link |
Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations.
Autoimmune type-II cryoglobulinemia (II-MC) is sustained by hepatitis C... | 30th October, 2009
| Experimental and Clinical Pharmacology Unit, Dipartimento di Oncologia
| Ann N Y Acad Sci. 2009 Sep;1173:152-60.
DOI Direct Link |
Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow.
We studied how integrin alpha2beta1 and glycoprotein VI (GPVI) contribute... | 29th October, 2009
| Department of Laboratory Medicine, Centro di Riferimento Oncologico (CRO)
| Blood. 2009 Sep 24;114(13):2793-801. Epub 2009 Jul 21.
DOI Direct Link |
→View more CRO research publications. |
Press Releases on CRO:
|
 |
| Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. |
18th November, 2009 |
Covance Inc. |
PRINCETON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of drug development services, announced today that it entered into a biomarker alliance and services
|
| SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise |
17th November, 2009 |
SIRO Clinpharm |
MUMBAI, India, Nov. 17 /PRNewswire/ -- SIRO Clinpharm, a global Contract Research Organization (CRO) with bases in India, US, Europe and Israel today announced their alliance with Mediscis, an early
|
| Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors |
13th November, 2009 |
Encorium Group, Inc. |
BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many
|
| ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009 |
13th November, 2009 |
ReSearch Pharmaceutical Services, Inc. |
-- Net income before provision for income taxes for the third quarter of
2009 of $2.2 million increased $0.9 million from $1.3 million for the
third quarter of 2008. Net income
|
| Pharmos Corporation Reports 2009 Third Quarter Results |
12th November, 2009 |
Pharmos Corporation |
ISELIN, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2009.
Third
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 55 individuals from CRO using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1496 times since April 2007, the link to the organisation's website has been followed 205 times Recent Search Terms used to find this page: RCT Inc. Russia | TOP 10 preclinical Cros of 2009 | autoimmune intestinal disease cro jobs | cel sci cro | Celiac Disease CRO | Celiac Disease CRO | cro in russia | russia cro | CRO Research Group | virology cro | . Search for more companies in Princeton Search for more companies in New Jersey This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for CRO |
